Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Prostatype Genomics AB's current 3-Year Share Buyback Ratio was -421.00%.
The historical rank and industry rank for Prostatype Genomics AB's 3-Year Share Buyback Ratio or its related term are showing as below:
OSTO:PROGEN'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -421 Med: -158.65 Max: -34.9
Current: -421
During the past 7 years, Prostatype Genomics AB's highest 3-Year Share Buyback Ratio was -34.90%. The lowest was -421.00%. And the median was -158.65%.
OSTO:PROGEN's 3-Year Share Buyback Ratio is ranked worse than 99.42% of 172
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.6
vs OSTO:PROGEN: -421.00
Prostatype Genomics AB (OSTO:PROGEN) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Prostatype Genomics AB 3-Year Share Buyback Ratio Related Terms
OSTO:PROGEN vs TMO, DHR, IDXX: 3-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB 3-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's 3-Year Share Buyback Ratio falls into.
Prostatype Genomics AB 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -421.00 mean?
Prostatype Genomics AB (OSTO:PROGEN) has a 3-Year Share Buyback Ratio of -421.00 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Prostatype Genomics AB and its competitors. According to the industry distribution chart, Prostatype Genomics AB ranks #171 out of 172 companies in the Medical Diagnostics & Research industry, placing it in the top 99.4%.
Is Prostatype Genomics AB's 3-Year Share Buyback Ratio too high?
Prostatype Genomics AB's current 3-Year Share Buyback Ratio is -421.00. Based on the distribution chart, Prostatype Genomics AB ranks #171 out of 172 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's 3-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #171 out of 172 companies for 3-Year Share Buyback Ratio. This places Prostatype Genomics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 3-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current 3-Year Share Buyback Ratio is -421.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.04, compared to a current price of kr0.16 — trading 290% above its estimated fair value. The current 3-Year Share Buyback Ratio is -421.00. Prostatype Genomics AB's overall GF Score™ is 23/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current 3-Year Share Buyback Ratio is -421.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.16 is trading 290% above its estimated GF Value™ of kr0.04.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
3-Year Share Buyback Ratio: -421.00
GF Value™: kr0.04 vs. price of kr0.16 (290% above fair value)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
23GF Score
Get the complete analysis for OSTO:PROGEN
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
